Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz

J A Markwalder; D D Christ; A Mutlib; B C Cordova; R M Klabe; S P Seitz

doi:10.1016/s0960-894x(01)00012-9

Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz

Bioorg Med Chem Lett. 2001 Mar 12;11(5):619-22. doi: 10.1016/s0960-894x(01)00012-9.

Authors

J A Markwalder¹, D D Christ, A Mutlib, B C Cordova, R M Klabe, S P Seitz

Affiliation

¹ DuPont Pharmaceuticals Company, Experimental Station, Wilmington, DE 19880-0500, USA. jay.a.markwalder@dupontpharma.com

PMID: 11266155
DOI: 10.1016/s0960-894x(01)00012-9

Abstract

Studies on the biotransformation of the clinically important non-nucleoside reverse transcriptase inhibitor efavirenz have shown that oxidation and secondary conjugation are important components of the processing of this molecule in vivo. We have synthesized metabolites of efavirenz to confirm their structure and to evaluate their activity as antivirals.

MeSH terms

Alkynes
Animals
Antiviral Agents / chemical synthesis*
Antiviral Agents / chemistry
Antiviral Agents / pharmacology*
Benzoxazines
Biotransformation
Cyclopropanes
Humans
Molecular Structure
Oxazines / metabolism*
Oxazines / pharmacology
Reverse Transcriptase Inhibitors / chemical synthesis*
Reverse Transcriptase Inhibitors / chemistry
Reverse Transcriptase Inhibitors / pharmacology*

Substances

Alkynes
Antiviral Agents
Benzoxazines
Cyclopropanes
Oxazines
Reverse Transcriptase Inhibitors
efavirenz